Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28669997 | 0.81 | CES2 (0.52) | CES2CES1CA1CA2MAPT | |
| SCHEMBL14040096 | 0.81 | CES2 (0.52) | CES2CES1CA1CA2MAPT | |
| SCHEMBL1553747 | 0.81 | HPGD (0.38) | GSK3BMAPTALDH1A1HPGDMEN1 | |
| SCHEMBL10384839 | 0.79 | CES2 (0.50) | CES2CES1CA1CA2MAPT | |
| SCHEMBL14040099 | 0.79 | CES2 (0.50) | CES2CES1CA1CA2MAPT | |
| SCHEMBL18360301 | 0.79 | CES2 (0.57) | CES2CES1ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1446377 | 0.78 | AKR1C1 (0.42) | GSK3BCES2CES1ALDH1A1HPGD | |
| SCHEMBL10458558 | 0.78 | CES2 (0.48) | CES2CES1CA1CA2MAPT | |
| SCHEMBL726159 | 0.78 | MEN1 (0.46) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL27265767 | 0.77 | HTT (0.41) | CA1CA2ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | claimed |
| US-6756502-B2 | AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE | ALEMBIC LIMITED (IN) | 2004-06-29 | — | — | US | claimed |
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) | 2003-10-16 | — | — | US | claimed |
| EP-1249447-A1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | Alembic Limited (IN) | 2002-10-16 | — | — | EP | claimed |
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | disclosed |
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | disclosed |
| US-6756502-B2 | AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE | ALEMBIC LIMITED (IN) | 2004-06-29 | — | — | US | disclosed |
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) | 2003-10-16 | — | — | US | disclosed |
| EP-1249447-A1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | Alembic Limited (IN) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | CYP3A4, CYP4X1, CYP2F1 | GSK3B 580/4885CES2 261/4885CES1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.